Skip to main content
Back to homepage
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Coverage Analysts
SEC Filings
SEC Filings
Annual Reports & Proxies
Governance
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Email Alerts
Contact
Menu
Press Releases
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Coverage Analysts
SEC Filings
SEC Filings
Annual Reports & Proxies
Governance
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Email Alerts
Contact
Normal
Press release year list
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
November 09, 2021
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 04, 2021
ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
November 02, 2021
ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
October 29, 2021
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
October 27, 2021
ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
September 29, 2021
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
September 27, 2021
ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors
September 23, 2021
ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 13, 2021
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®
September 09, 2021
ADC Therapeutics to Participate in Morgan Stanley’s 19th Annual Global Healthcare Conference
September 03, 2021
ADC Therapeutics Announces Medical Leadership Transition
August 26, 2021
ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million
August 03, 2021
ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
July 28, 2021
ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021
June 22, 2021
ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma
June 18, 2021
ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
June 11, 2021
ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
June 09, 2021
ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma
June 04, 2021
ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting
May 27, 2021
ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference
May 26, 2021
ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology
May 19, 2021
ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting
May 17, 2021
ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield
May 12, 2021
ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology
May 06, 2021
ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
May 05, 2021
ADC Therapeutics’ ZYNLONTA™ (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell Lymphomas
May 04, 2021
ADC Therapeutics to Participate in May Investor Conferences
April 29, 2021
ADC Therapeutics to Host First Quarter 2021 Financial Results Conference Call on May 6, 2021
April 23, 2021
ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
April 06, 2021
Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer
March 18, 2021
ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updates
March 11, 2021
ADC Therapeutics to Host Fourth Quarter and Year-End 2020 Financial Results Conference Call on March 18, 2021
February 25, 2021
ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference
February 05, 2021
ADC Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
February 04, 2021
ADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
January 07, 2021
ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S.
January 04, 2021
ADC Therapeutics to Participate in SternIR Virtual Corporate Access Event